You searched for "training"
Sustainable healthcare: what steps can urologists take?
Human health is intrinsically linked to environmental health, making the ever-pressing climate crisis fundamentally a public health emergency. The healthcare sector is responsible for 8% of the UK’s greenhouse gas (GHG) emissions worldwide [1]. As the largest publicly funded healthcare...Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...Fournier’s gangrene
Introduction Fournier’s gangrene (FG) is a rare but fulminant form of infective necrotising fasciitis affecting the perineum and external genitalia, which can rapidly progress along fascial planes. It most commonly affects men, but can occur in women and children, with...TUF in the time of coronavirus
At The Urology Foundation (TUF) we are acutely aware that the attention of our colleagues in the urology profession are rightly elsewhere at the moment. I would like to thank all urologists, urology nurses and urology researchers for the ...
Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy
The functional side-effects of both radical prostatectomy and radiotherapy for prostate cancer are well known. The aim of this study was to evaluate if there was a significant worsening in recovery of urinary continence in those undergoing radical prostatectomy followed...Opening up about incontinence
This year, the EAU’s Urology Week is shining the spotlight on incontinence because it is still a taboo subject, with many people struggling to talk to a health professional, partner or even a friend about it.
Solifenacin and mirabegron are safe and effective in combination
Antimuscarinic agents remain the mainstay of medical management of bladder overactivity. Limited somewhat by their tolerability, the new agent mirabegron, a β3-adrenoreceptor agonist, has been approved as an alternative. There is little known however about the possible synergistic effects of...
